Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P737: The use of infliximab therapeutic drug monitoring in virtual biologics clinic for inflammatory bowel disease (IBD) leads to clinically durable resultsECCO '18 Vienna
Year: 2018
Authors:

R. Sagar1, M. Lenti1, T. Clark1, H. Rafferty1, D. Gracie1, A. Ford1, A. O'Connor1, J. Hamlin1, T. Ahmad2, C. Selinger1*

1St James University Hospital, Gastroenterology, Leeds, UK, 2Royal Devon and Exeter Foundation Trust, Gastroenterology, Exeter, UK

P738: Sustained clinical remission with vedolizumab in Moderate-to-Severe Crohn’s disease: A GEMINI 2 post hoc analysis of Week 14 remittersECCO '18 Vienna
Year: 2018
Authors:

R. Hardi1, B. Bokemeyer2, W. Sandborn3, W. Reinisch4, I. Shafran5, A. Stallmach6, R. Ehehalt7, P. Geransar8*, J.M. Khalid9, D. Tudor10, S. Schreiber11

1Capital Digestive Care, Chevy Chase Clinical Research, Chevy Chase, USA, 2Gastroenterology Practice, Minden, Germany, 3University of California San Diego, Division of Gastroenterology, La Jolla, USA, 4Medical University of Vienna, Department Internal Medicine III, Vienna, Austria, 5Shafran Gastroenterology Research Center, Winter Park, USA, 6Jena University Hospital, Department of Internal medicine IV, Jena, Germany, 7Praxis für Gastroenterologie, Heidelberg, Germany, 8Takeda Pharmaceuticals International AG, Global Medical Affairs, Zurich, Switzerland, 9Takeda Development Centre Europe Ltd., Evidence and Value Generation, London, UK, 10Takeda Pharmaceuticals International AG, Zurich, Switzerland, 11Christian-Albrechts-University, Institute for Clinical Molecular Biology, Kiel, Germany

P739: Early use of anti-TNF in Crohn’s disease is associated with higher rate of biological and endoscopic remissionECCO '18 Vienna
Year: 2018
Authors:

M.P. Costa Santos*, C. Gouveia, C. Palmela, C. Fidalgo, L. Glória, M. Cravo, J. Torres

Hospital Beatriz Ângelo, Gastroenterology Department, Loures, Portugal

P740: Efficacy and safety of vedolizumab in inflammatory bowel disease: Real-life experienceECCO '18 Vienna
Year: 2018
Authors:

C. González Muñoza1, F. Mesonero2, A. Bargalló3, A. Clos4, C. Aràjol5, J. Gordillo1*, A. López- San Román2, J. Guardiola5, M. Navarro-Llavat3, F. Bertoletti1, C. Fernández2, E. Domènech4,6, E. Garcia-Planella1

1Hospital Santa Creu i Sant Pau, Barcelona, Spain, 2Hospital Ramón y Cajal, Madrid, Spain, 3Hospital Moisès Broggi, Sant Joan Despi, Spain, 4Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 5Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain, 6Ciberehd, Madrid, Spain

P741: Very high rate of tuberculosis complicating infliximab therapy for inflammatory bowel disease despite tuberculosis screening in IndiaECCO '18 Vienna
Year: 2018
Authors:

A. Agarwal*, S. Kedia, S. Jain, V. Gupta, S. Bopanna, D. Yadav, S. Goyal, P.M. Venegella, G. Makharia, V. Ahuja

All India Institute Of Medical Sciences, Gastroenterology and Human Nutrition, New Delhi, India

P742: Long-term outcome of patients with ulcerative colitis and first course of intravenous corticosteroidsECCO '18 Vienna
Year: 2018
Authors:

H. Eronen1*, P. Oksanen1,2, A. Jussila1

1Tamperee University Hospital, Gastroenterology, Tampere, Finland, 2Tampere University, Tampere, Finland

P743: Ustekinumab use in Crohn´s Disease: Does short-term effectiveness correlate to induction regimen?ECCO '18 Vienna
Year: 2018
Authors:

A. Gutiérrez1,2*, L. Sempere1, R. Laveda3, M.F. García4

1Hospital General Universitario Alicante, Alicante, Spain, 2CIBERehd, Madrid, Spain, 3Hospital San Juan, Alicante, Spain, 4Hospital General Universitario Elche, Elche, Spain

P744: Therapeutic gain of continued, long-term infliximab therapy in Crohn’s disease patients with response but non-remission after one year of infliximab therapyECCO '18 Vienna
Year: 2018
Authors:

S. Buhl*, M.K. Borghede, J. Brynskov, C. Steenholdt, M. Rasmussen, M.A. Ainsworth

Copenhagen University Hospital, Herlev, Department of Gastroenterology, Herlev, Denmark

P745: Switching between anti-TNF originator and biosimilar in patients with inflammatory bowel disease: Can it be recommended? A systematic reviewECCO '18 Vienna
Year: 2018
Authors:

J.P. Gisbert1,2,3,4*, M. Chaparro1,2,3,4

1Hospital Universitario de La Princesa, Gastroenterology Unit, Madrid, Spain, 2Instituto de Investigación Sanitaria Princesa (IIS-IP), Madrid, Spain, 3Universidad Autónoma de Madrid, Madrid, Spain, 4Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain

P746: Anthropometric measures in adolescents with inflammatory bowel disease: A population-based studyECCO '18 Vienna
Year: 2018
Authors:

I. Ghersin1*, L.H. Katz2, S. Daher3, R. Shamir4, A. Assa4

1Rambam Health Care Campus, Haifa, Israel, 2Sheba Medical Center, Gastroenterology, Ramat Gan, Israel, 3IDF Medical Corps, Tel Hashomer, Israel, 4Schneider Children's Medical Center, Gastroenterology, Petach Tikva, Israel

P747: Predictors of thiopurine treatment failure in ulcerative colitisECCO '18 Vienna
Year: 2018
Authors:

S.H. Hwang1*, J.S. Koo1, K.H. Kang1, D.-w. Lee1, B.J. Lee2, Y.T. Jeen3

1Korea University Ansan Hospital, Division of Gastroenterology and Hepatology, Ansan, South Korea, 2Korea University Guro Hospital, Division of Gastroenterology and Hepatology, Seoul, South Korea, 3Korea University Anam Hospital, Division of Gastroenterology and Hepatology, Seoul, South Korea

P748: Clinical outcomes and prognostic factors of methotrexate therapy in combination with anti-TNF agents in inflammatory bowel diseaseECCO '18 Vienna
Year: 2018
Authors:

J. Park1,2*, J.H. Cheon1,2, J.J. Park3, Y. Park1,2, S.J. Park1,2, T.I. Kim1,2, W.H. Kim1,2

1Yonsei University College of Medicine, Department of Internal Medicine, Seoul, South Korea, 2Yonsei University College of Medicine, Institute of Gastroenterology, Seoul, South Korea, 3Gangnam Severance Hospital, Yonsei University College of Medicine, Department of Internal Medicine, Institute of Gastroenterology, Seoul, South Korea

P749: A comparative analysis of low bioavailability steroids in inducing clinical response and remission in ulcerative colitis: Budesonide MMX as the safest optionECCO '18 Vienna
Year: 2018
Authors:

B. Scrivo, E. Giuffrida, V. Calvaruso, M. Cappello*

Gastroenterology Section, DiBiMis, University of Palermo, Palermo, Italy

P750: Predictors of quick remission after cyclosporine A therapy in Paediatric ulcerative colitisECCO '18 Vienna
Year: 2018
Authors:

M. Osiecki*, M. Dadalski, J. Kierkus

The Children's Memorial Health Institute, Gastroenterology, Hepatology, Feeding Disorders and Paediatrics, Warsaw, Poland

P751: Time course of the incidence and magnitude of anti-drug antibodies to adalimumab and ABP 501 among patients on concomitant immunomodulatory therapyECCO '18 Vienna
Year: 2018
Authors:

D. Mytych*, J. Miller, M. Starcevic Manning, I. Wala, H. Wang, N. Zhang, E. Krishnan, A. Kaliyaperumal

Amgen Inc., Biosimilars, Thousand Oaks, USA

P752: Oral once daily budesonide granules rapidly induce clinical remission in Lymphocytic Colitis: A double-blind, double-dummy, multi-centre, randomised trialECCO '18 Vienna
Year: 2018
Authors:

S. Miehlke1*, D. Aust2, E. Mihaly3, P. Armerding4, G. Böhm5, O. Bonderup6, F. Fernández-Bañares7, J. Kupcinskas8, L.K. Munck9, K.-U. Rehbehn10, T. Nacak11, R. Greinwald11, A. Münch12

1Center for Inflammatory and Digestive Diseases Eppendorf, Hamburg, Germany, 2University Hospital, Institute of Pathology, Dresden, Germany, 3Semmelweis University, Budapest, Hungary, 4Private Practice for Gastroenterology, Berlin, Germany, 5Private Practice, Ludwigshafen, Germany, 6Silkeborg Hospital, Diagnostic Center, Silkeborg, Denmark, 7Hospital Universitari Mutua Terrassa, Department of Gastroenterology, Terrassa, Spain, 8University of Health Sciences, Kaunas, Lithuania, 9Køge Hospital, Department of Medical Gastroenterology, Køge, Denmark, 10Private Practice, Solingen, Germany, 11Dr. Falk Pharma GmbH, Clinical Research, Freiburg, Germany, 12Linköping University, Division of Gastroenterology and Hepatology, Linköping, Germany

P753: Vedolizumab trough levels during induction in IBD patients: A longitudinal observational retrospective studyECCO '18 Vienna
Year: 2018
Authors:

C. Liefferinckx1,2*, A. Cremer1,2, C. Minsart2, A. Gils3, L. Amininejad1, V. Tafciu2, E. Quertinmont2, J. Devière1,2, A. Van Gossum1, D. Franchimont1,2

1Hopital Erasme, ULB, Department of gastroenterology, Brussels, Belgium, 2Université libre de bruxelles, Laboratory of Experimental Gastroenterology, Brussels, Belgium, 3KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium

P754: Short-term and long-term outcome for dilation therapy of stricturing Crohn’s disease of the small intestine using balloon-assisted endoscopy - a combined analysis of 1194 endoscopic balloon dilation proceduresECCO '18 Vienna
Year: 2018
Authors:

D. Bettenworth1,2*, A. Bokemeyer1, R. Lopez3, F. Rieder4,5

1University Hospital Münster, Department of Medicine B, Gastroenterology and Hepatology, Münster, Germany, 2University Hospital Münster, Department of Medicine B, Münster, Germany, 3Cleveland Clinic Foundation, Cleveland, Ohio, USA, Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland, USA, 4Cleveland Clinic Foundation, Cleveland, Ohio, USA, Department of Gastroenterology, Hepatology and Nutrition, Digestive Disease Institute, Cleveland, USA, 5Cleveland Clinic Foundation, Cleveland, Ohio, USA, Department of Pathobiology, Lerner Research Institute, Cleveland, USA

P755: Safety, efficacy, and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an anti-TNFECCO '18 Vienna
Year: 2018
Authors:

S. Ben-Horin1*, B. Ungar1, U. Kopylov1, A. Lahat1, M. Yavzori1, E. Fudim1, O. Picard1, Y. Peled2, R. Eliakim1, E. Del Tedesco3, S. Paul4, X. Roblin4

1Sheba Medical Center and Sackler School of Medicine, Gastroenterology, Tel Hashomer, Israel, 2Sheba Medical Center and Sackler School of Medicine, Institute of Clinical Pharmacology, Tel Hashomer, Israel, 3CHU de Saint-Etienne, Service de Gastrologie-Entérologie-Hépatologie, Saint-Etienne, France, 4University Hospital of Saint Etienne, Department of Gastroenterology, Saint Etienne, France

P756: Comorbidities in adolescents with inflammatory bowel disease: Findings from a population-based cohortECCO '18 Vienna
Year: 2018
Authors:

I. Ghersin1*, L.H. Katz2, S. Daher3, R. Shamir4, A. Assa4

1Rambam Health Care Campus, Haifa, Israel, 2Sheba Medical Center, Gastroenterology, Ramat Gan, Israel, 3IDF Medical Corps, Tel Hashomer, Israel, 4Schneider Children's Medical Center, Gastroenterology, Petach Tikva, Israel